Inducible nitric oxide synthase (iNOS) in muscle wasting syndrome, sarcopenia, and cachexia

Derek T. Hall, Jennifer F. Ma, Sergio Di Marco, Imed Gallouzi

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Muscle atrophy-also known as muscle wasting-is a debilitating syndrome that slowly develops with age (sarcopenia) or rapidly appears at the late stages of deadly diseases such as cancer, AIDS, and sepsis (cachexia). Despite the prevalence and the drastic detrimental effects of these two syndromes, there are currently no widely used, effective treatment options for those suffering from muscle wasting. In an attempt to identify potential therapeutic targets, the molecular mechanisms of sarcopenia and cachexia have begun to be elucidated. Growing evidence suggests that inflammatory cytokines may play an important role in the pathology of both syndromes. As one of the key cytokines involved in both sarcopenic and cachectic muscle wasting, tumor necrosis factor a (TNFa) and its downstream effectors provide an enticing target for pharmacological intervention. However, to date, no drugs targeting the TNFa signaling pathway have been successful as a remedial option for the treatment of muscle wasting. Thus, there is a need to identify new effectors in this important pathway that might prove to be more efficacious targets. Inducible nitric oxide synthase (iNOS) has recently been shown to be an important mediator of TNFa-induced cachectic muscle loss, and studies suggest that it may also play a role in sarcopenia. In addition, investigations into the mechanism of iNOS-mediated muscle loss have begun to reveal potential therapeutic strategies. In this review, we will highlight the potential for targeting the iNOS/NO pathway in the treatment of muscle loss and discuss its functional relevance in sarcopenia and cachexia.

Original languageEnglish
Pages (from-to)702-715
Number of pages14
JournalAging
Volume3
Issue number8
Publication statusPublished - Aug 2011
Externally publishedYes

Fingerprint

Sarcopenia
Wasting Syndrome
Cachexia
Nitric Oxide Synthase Type II
Muscles
Tumor Necrosis Factor-alpha
Cytokines
Therapeutics
Muscular Atrophy
Drug Delivery Systems
Sepsis
Acquired Immunodeficiency Syndrome
Pharmacology
Pathology

ASJC Scopus subject areas

  • Ageing
  • Cell Biology
  • Geriatrics and Gerontology

Cite this

Inducible nitric oxide synthase (iNOS) in muscle wasting syndrome, sarcopenia, and cachexia. / Hall, Derek T.; Ma, Jennifer F.; Marco, Sergio Di; Gallouzi, Imed.

In: Aging, Vol. 3, No. 8, 08.2011, p. 702-715.

Research output: Contribution to journalArticle

Hall, Derek T. ; Ma, Jennifer F. ; Marco, Sergio Di ; Gallouzi, Imed. / Inducible nitric oxide synthase (iNOS) in muscle wasting syndrome, sarcopenia, and cachexia. In: Aging. 2011 ; Vol. 3, No. 8. pp. 702-715.
@article{7fe8d11ef4a14339bcbb7672fdc26d66,
title = "Inducible nitric oxide synthase (iNOS) in muscle wasting syndrome, sarcopenia, and cachexia",
abstract = "Muscle atrophy-also known as muscle wasting-is a debilitating syndrome that slowly develops with age (sarcopenia) or rapidly appears at the late stages of deadly diseases such as cancer, AIDS, and sepsis (cachexia). Despite the prevalence and the drastic detrimental effects of these two syndromes, there are currently no widely used, effective treatment options for those suffering from muscle wasting. In an attempt to identify potential therapeutic targets, the molecular mechanisms of sarcopenia and cachexia have begun to be elucidated. Growing evidence suggests that inflammatory cytokines may play an important role in the pathology of both syndromes. As one of the key cytokines involved in both sarcopenic and cachectic muscle wasting, tumor necrosis factor a (TNFa) and its downstream effectors provide an enticing target for pharmacological intervention. However, to date, no drugs targeting the TNFa signaling pathway have been successful as a remedial option for the treatment of muscle wasting. Thus, there is a need to identify new effectors in this important pathway that might prove to be more efficacious targets. Inducible nitric oxide synthase (iNOS) has recently been shown to be an important mediator of TNFa-induced cachectic muscle loss, and studies suggest that it may also play a role in sarcopenia. In addition, investigations into the mechanism of iNOS-mediated muscle loss have begun to reveal potential therapeutic strategies. In this review, we will highlight the potential for targeting the iNOS/NO pathway in the treatment of muscle loss and discuss its functional relevance in sarcopenia and cachexia.",
author = "Hall, {Derek T.} and Ma, {Jennifer F.} and Marco, {Sergio Di} and Imed Gallouzi",
year = "2011",
month = "8",
language = "English",
volume = "3",
pages = "702--715",
journal = "Aging",
issn = "0002-0966",
publisher = "US Administration on Aging",
number = "8",

}

TY - JOUR

T1 - Inducible nitric oxide synthase (iNOS) in muscle wasting syndrome, sarcopenia, and cachexia

AU - Hall, Derek T.

AU - Ma, Jennifer F.

AU - Marco, Sergio Di

AU - Gallouzi, Imed

PY - 2011/8

Y1 - 2011/8

N2 - Muscle atrophy-also known as muscle wasting-is a debilitating syndrome that slowly develops with age (sarcopenia) or rapidly appears at the late stages of deadly diseases such as cancer, AIDS, and sepsis (cachexia). Despite the prevalence and the drastic detrimental effects of these two syndromes, there are currently no widely used, effective treatment options for those suffering from muscle wasting. In an attempt to identify potential therapeutic targets, the molecular mechanisms of sarcopenia and cachexia have begun to be elucidated. Growing evidence suggests that inflammatory cytokines may play an important role in the pathology of both syndromes. As one of the key cytokines involved in both sarcopenic and cachectic muscle wasting, tumor necrosis factor a (TNFa) and its downstream effectors provide an enticing target for pharmacological intervention. However, to date, no drugs targeting the TNFa signaling pathway have been successful as a remedial option for the treatment of muscle wasting. Thus, there is a need to identify new effectors in this important pathway that might prove to be more efficacious targets. Inducible nitric oxide synthase (iNOS) has recently been shown to be an important mediator of TNFa-induced cachectic muscle loss, and studies suggest that it may also play a role in sarcopenia. In addition, investigations into the mechanism of iNOS-mediated muscle loss have begun to reveal potential therapeutic strategies. In this review, we will highlight the potential for targeting the iNOS/NO pathway in the treatment of muscle loss and discuss its functional relevance in sarcopenia and cachexia.

AB - Muscle atrophy-also known as muscle wasting-is a debilitating syndrome that slowly develops with age (sarcopenia) or rapidly appears at the late stages of deadly diseases such as cancer, AIDS, and sepsis (cachexia). Despite the prevalence and the drastic detrimental effects of these two syndromes, there are currently no widely used, effective treatment options for those suffering from muscle wasting. In an attempt to identify potential therapeutic targets, the molecular mechanisms of sarcopenia and cachexia have begun to be elucidated. Growing evidence suggests that inflammatory cytokines may play an important role in the pathology of both syndromes. As one of the key cytokines involved in both sarcopenic and cachectic muscle wasting, tumor necrosis factor a (TNFa) and its downstream effectors provide an enticing target for pharmacological intervention. However, to date, no drugs targeting the TNFa signaling pathway have been successful as a remedial option for the treatment of muscle wasting. Thus, there is a need to identify new effectors in this important pathway that might prove to be more efficacious targets. Inducible nitric oxide synthase (iNOS) has recently been shown to be an important mediator of TNFa-induced cachectic muscle loss, and studies suggest that it may also play a role in sarcopenia. In addition, investigations into the mechanism of iNOS-mediated muscle loss have begun to reveal potential therapeutic strategies. In this review, we will highlight the potential for targeting the iNOS/NO pathway in the treatment of muscle loss and discuss its functional relevance in sarcopenia and cachexia.

UR - http://www.scopus.com/inward/record.url?scp=84055202659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84055202659&partnerID=8YFLogxK

M3 - Article

C2 - 21832306

AN - SCOPUS:84055202659

VL - 3

SP - 702

EP - 715

JO - Aging

JF - Aging

SN - 0002-0966

IS - 8

ER -